Back to discover
Disease

Hirsutism

Late-stage therapeutic developmentEmerging research
MeSHHirsutism
2
Publications
5
Clinical trials
2019
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Eflornithineapproved

Approval — Treatment of facial hirsutism in women. (2001)

Clinical trials

5 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
5
All trials
0
Active
2
Late-stage
5
Completed
Recently completed

A Randomised, Double-blind, Placebo-controlled Trial of FOL-005 to Investigate Clinical Safety and Effect on Hair Growth in Healthy Volunteers

Phase 1/2 · Completed · Follicum AB

Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone: Effects of Six Months Treatment on Clinical, Endocrine and Metabolic Features in Obese Women With Polycystic Ovary Syndrome

N/A · Completed · Catholic University of the Sacred Heart

Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism

Phase 4 · Completed · Bispebjerg Hospital

The Efficacy of Topical Finasteride in the Treatment of Idiopathic Hirsutism

N/A · Completed · Iran University of Medical Sciences

A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women With Excessive Facial Hair

Phase 4 · Completed · Allergan

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2001emaApproval — Eflornithine· Treatment of facial hirsutism in women. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20102019
Major themes3
  • Cosmetic Techniques1
  • Esthetics1
  • Transgender Persons1
Leading journals2
  • BMC medicine1
  • Journal of the American Academy of Dermatology1
Leading researchers8
  • Bonati LM1
  • Chou M1
  • Deeks A1
  • Dhingra N1
  • Jagdeo J1
  • Moran L1
  • Teede H1
  • Wang EB1
Affiliations (unnormalised)3
  • Icahn School of Medicine at Mount Sinai1
  • Monash University1
  • University of California at Davis1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.

Identifiers
MeSHHirsutism
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.